Both Phrma (the lobby for the global pharmaceutical industry) and Biotechnology Innovation Organization (biotech lobbyists) provided letters to a US-UK government meeting to discuss post-Brexit trade terms, in which both organisations called for substantially higher British prices for essential medicines after Brexit.
Read the rest
KSU plant biochemical geneticist Raj Nagarajan describes the properties of Thaumatin, Monellin and Brazzein, all found in west African plants that are generally considered safe for consumption; each is a protein, and they are, respectively, 1,000x, 2000x, and 3000x sweeter than sugar. Read the rest
Nick Bilton's analysis of his Theranos exposé shows how bad actors like Elizabeth Holmes can misuse employees and government regulators, but he is especially critical of access journalism practiced in the business trades. It's a great read for anyone who writes as part of their job. Read the rest
Meet Saqib, a Microsoft dev in London who lost the use of his eyes at age 7. Here's a neat little profile of his artificial intelligence development work from Microsoft Cognitive Services: Read the rest
Eliza writes, "A researcher from Lehigh University has invented a light-based pacemaker for fruit flies, and says a human version is 'not impossible.' The pacemaker relies on the new technique of 'optogenetics,' in which light-sensitive proteins are inserted into certain cells, allowing those cells to be activated by pulses of light. Here, the proteins were inserted into cardiac cells so the researchers could trigger the contractions that produce heartbeats." Read the rest
Ramez Naam's Nexus trilogy
has concluded with a huge, thrilling, globe-spanning book called Apex
that nailed it
Today, Google announced the launch of Calico, a new company that will "focus on health and well-being, in particular the challenge of aging and associated diseases."
Former Genentech CEO Arthur D. Levinson, who is Chairman of the Board at both Genentech and Apple, is CEO and a founding investor of the new Google spinoff venture.
Noted Google+ user Larry Page posts this morning:
OK … so you’re probably thinking wow! That’s a lot different from what Google does today. And you’re right. But as we explained in our first letter to shareholders, there’s tremendous potential for technology more generally to improve people’s lives. So don’t be surprised if we invest in projects that seem strange or speculative compared with our existing Internet businesses. And please remember that new investments like this are very small by comparison to our core business. Art and I are excited about tackling aging and illness. These issues affect us all—from the decreased mobility and mental agility that comes with age, to life-threatening diseases that exact a terrible physical and emotional toll on individuals and families. And while this is clearly a longer-term bet, we believe we can make good progress within reasonable timescales with the right goals and the right people.
Hey, none of this health and wellness stuff should come as a surprise to internet old-timers who recall when the "web crawler" was named "BackRub."
Time has an exclusive, in this week's cover story at the magazine. The short version: "the company behind YouTube and Google+ is gearing up to seriously attempt to extend human lifespan." Read the rest
The American Quarter Horse Association has been ordered to accept cloned horses into its registry by a jury in the courtoom of U.S. District Court Judge Mary Lou Robinson. They were sued by a pair of Texas breeders, who said the organization's practice of excluding cloned horses was monopolistic. The judge did rule on awarding costs to the breeders, who spent some $900,000 on the case. Read the rest
Pseudopterosins are a family of naturally occurring chemicals with the power to reduce inflammation, skin irritation, and pain. In other words, they make a great additive in skin cream. If you want skin that less red, pseudopterosins can help. Want a lotion that soothes your face after a particularly vigorous round of exfoliation? Call on pseudopterosins.
Pseudopterosins come from a coral called Pseudopterogorgia elisabethae. That's it in the photo above. For years, researchers and pharmaceutical companies thought they were sustainably harvesting P. elisabethae because, instead of simply gathering any of the coral they could find, they merely pruned it — leaving plenty of the creature to grow back.
But, it turns out that this is a really good example of a frustrating problem — what seems sustainable is not always actually sustainable. Doing the right thing, environmentally speaking, isn't as intuitive as we'd like it to be. (Also, pruning an animal isn't like pruning a plant.) At Deep Sea News, Dr. M explains:
Read the rest
After prunings in 2002 and 2005 and before the annual spawning, Christopher Page and Howard Lasker examined 24 pruned corals and 20 unpruned corals. What the researchers found is that although colonies appeared healthy pruned corals produced less eggs. ... Why would pruned corals produce less eggs and sperm? When organisms are injured more energy is diverted away from reproduction and toward repair. Interestingly, this pruning may actually also creating artificial selection. If workers are targeting larger and fuller corals to prune, then smaller less thick corals will be reproducing more and eventually become more dominant.
More than 100 biomedical and life science companies are clustered in Genome Valley, a research park in Hyderabad, India. (Via Joanne Manaster) Read the rest
The Guerrilla Grafters are a group of rogue artists who roam San Francisco, covertly grafting fruit-tree branches onto ornamental trees to create a municipal free lunch. John Robb calls it "resilient disobedience."
How can you improve the productivity of your community even if the officials are against it?
One way is through resilient disobedience. For example, there’s a group of gardeners in San Francisco that are spreading organic graffiti across the city. How? By grafting branches from fruit trees onto ornamental trees that have been planted along sidewalks and in parks.
They are using a very simple tongue in groove splice that’s held together with annotated electrical tape. Good luck to them.
Personal Biochar Kilns, Portable Factories, DiY Septic Tank Cleaning, and Guerrilla Grafting
(via Warren Ellis) Read the rest
British biotechnology company Oxitec Ltd is trying to convince the locals in Key West to use genetically modified mosquitoes in their fight to eradicate dengue fever in the area. What could possibly go wrong? Read the rest
When you have been diagnosed with cancer, as I have, you quickly grow accustomed to "friendly cancer spam." Friends, relatives, and well-meaning acquaintances routinely forward you a gazillion identical links to whatever this week's hot cancer news headline may be.
So it was for me with this New York Times story on Lukas Wartman, a leukemia doctor and researcher at Washington University who developed leukemia. As he faced death last Fall, his cancer genome was sequenced by his colleagues.
What was revealed then led to a treatment plan that targeted the specifics of his genetic makeup. And so far, according to Gina Kolata's report, that experimental treatment plan has been an amazing success. Snip:
Read the rest
Dr. Ley’s team tried a type of analysis that they had never done before. They fully sequenced the genes of both his cancer cells and healthy cells for comparison, and at the same time analyzed his RNA, a close chemical cousin to DNA, for clues to what his genes were doing.
The researchers on the project put other work aside for weeks, running one of the university’s 26 sequencing machines and supercomputer around the clock. And they found a culprit — a normal gene that was in overdrive, churning out huge amounts of a protein that appeared to be spurring the cancer’s growth.
Even better, there was a promising new drug that might shut down the malfunctioning gene — a drug that had been tested and approved only for advanced kidney cancer. Dr. Wartman became the first person ever to take it for leukemia.
Here's an amazing feel-good video with which to end your week, via the National Science Foundation. The really awesome footage starts around a minute and a half in.
"James C. (Cole) Galloway, associate professor of physical therapy, and Sunil Agrawal, professor of mechanical engineering -- have outfitted kid-size robots to provide mobility to children who are unable to fully explore the world on their own."
The robotic assistance devices are designed to help infants whose mobility and independence is limited by conditions such as autism, spina bifida, muscular dystrophy, Down syndrome, and cerebral palsy.
I understand that these will be among the many exhibits on display at the USA Science Fest at the Washington, DC Convention Center on Sat., April 28th. Babies probably not included. Read the rest
Robbo sez, "In the age of 3D printing and growing new body parts in a lab - the fashion industry steps forth and joins the fray - using bacteria to grow clothing. As described in a post on the ecouterre.com site:
'designer Suzanne Lee has crafted fashion items that look both cool and unsettling. No doubt we'll all soon be wearing clothing we can print out or grow - purchasing designs online and then heading down to the kitchen to try things on. Biodegradable? Possibly. Could also be used to thicken gravy.'
(Thanks, Robbo) Read the rest
The coal-fired baking of bricks generates more CO2 annually than the entire aviation industry. A biomanufacturing process aims to change that, replacing fire with a mixture of non-pathogenic bacteria and sand. It's cheap, and the inventor, Professor Ginger Dosier, says it produces better and more sustainable bricks.
There are over 1.3 trillion bricks manufactured each year worldwide, and over 10% are made by hand in coal-fired ovens. On average, the baking process emits 1.4 pounds of carbon per brick - more than the world's entire aviation fleet. In countries like India and China, outdated coal-fired brick kilns consume more energy, emit more carbon, and produce great quantities of particulate air pollution. Dosier's process replaces baking with simple mixing, and because it is low-tech (apart from the production of the bacterial activate), can be done onsite in localities without modern infrastructure. The process uses no heat at all:mixing sand and non-pathogenic bacteria (sporosar) and putting the mixture into molds. The bacteria induce calcite precipitation in the sand and yield bricks with sandstone-like properties. If biomanufactured bricks replaced each new brick on the planet, it would save nearly 800 million tons of CO2 annually.
Biomanufactured Brick: Bricks Without Clay or Carbon
(via Beyond the Beyond)
Best Buy allegedly sells brick in a box ... again
How To: build the ultimate, cheap home pizza oven Read the rest
United States District Court Judge Robert W. Sweet has invalidated Myriad Genetics's infamous "breast cancer patent" -- a patent on genetic mutations that cause breast cancer, which Myriad has exercised in the form of a high lab-fee for analysis on samples (Myriad threatens to sue any independent lab that performs the analysis).
The suit was brought by the ACLU and the Public Patent Foundation, who argued that US Patent and Trademark Office was wrong to grant patents on genes, as these are not patentable subject matter. The judge agreed, saying that gene patents are patents on a "law of nature" and called the isolation of genes and filing patents on them "a lawyer's trick that circumvents the prohibition on the direct patenting of the DNA in our bodies but which, in practice, reaches the same result."
Which sounds to me like a precedent against all patents that rely on isolated genes. Of course, this isn't over: the pharma/biotech stalwarts interviewed in the linked NYT piece are talking appeal, and I'm sure they'll try to go all the way to the Supreme Court.
I think that the problem here is in the untested idea that imparting exclusive rights to the genome will incentivize more research than allowing anyone to build on discoveries in the genome. It's clear that some exclusive rights provide an incentive so some people to do work. But these exclusive rights also scare off people who have good ideas but are worried about being bankrupted by someone who beat them to the patent. Read the rest